Capacity inflection and semaglutide scaling — what Q2 must show
OneSource enters earnings season on oversold technicals but with Street backing: 3-of-4 analysts rate Buy, eyeing 27% upside to ₹2,056. The question for Oct 27 is whether Q2 revenue momentum sustains semaglutide's Canada/India ramp and delivers on the second cartridge line coming online. Margins and guidance will matter more than the raw print.
The setup: revenue inflection meets execution risk
Q1 FY27 marked a turning point—OneSource posted ₹449 Cr revenue (up 37% YoY) and ₹123 Cr EBITDA (up 39% YoY), swinging to a ₹25 Cr consolidated profit from a ₹0.2 Cr loss a year prior. The driver: semaglutide launches in Canada and India, now supplying over 40% of India's generic pens market, plus new MSA contracts and biologics wins. Q2 enters with two tailwinds—semaglutide commercialization accelerating into the second quarter of the fiscal year, and the second cartridge line scheduled to begin commercial operations, unlocking capacity. The Street is backing the narrative: 3 of 4 analysts rate Buy, targeting ₹2,056 on average (+27% upside from today's ₹1,377.8). But the stock is oversold (RSI 29.5), and sentiment has deteriorated sharply from recent highs (₹2,248, now -38.7%). Q2 results will test whether the growth story justifies consensus or whether margins crack under new capacity ramp and semaglutide volume competition.
What to expect: the metric grid
~₹550–600 Cr
Extrapolating Q1's 37% YoY trajectory and semaglutide volume uptick into Q2; on-plan assumes momentum sustains
₹150–170 Cr
Q1 ran 27.4% margin; Q2 to test margin sustainability as second cartridge ramps; guidance-aligned for FY28 40% target
Expected material contributor
Company clarified DRL supply delays have no material impact (Jul 9); in-house India launches should offset. Watch for % of total in Q2.
Ramp-in phase
Second line goes live in Q2. Early stage; efficiency gains will likely lag FY28 guidance. Key for long-term margin trajectory.
A strong Q2 print would show: (1) revenue north of ₹570 Cr (sustaining 35%+ YoY growth), (2) semaglutide revenue as a named line item and visibly ramping, (3) EBITDA margin holding at or near 27%, and (4) management guidance reaffirming FY28 targets of $400m organic revenue and 40% EBITDA margin. A weak Q2 would flag: (1) revenue miss vs. the ~550 Cr run-rate (semaglutide uptake slower than expected, or competitive pressure), (2) margin compression below 25% (new capacity overhead eating into profitability), or (3) any watering down of FY28 guidance (capacity ramp cost higher, or volume shortfalls).
On track to FY28 targets?
Q1 set a high bar—37% revenue growth and 39% EBITDA growth—but the company had guided to $400m (approx ₹3,300 Cr annualized) organic revenue by FY28 with 40% EBITDA margin. Q2 is a proof point: can OneSource sustain 30%+ YoY growth through the full year while absorbing the cost and operational complexity of a second cartridge line coming online? The second production line is not yet at steady-state, so Q2 will show early utilization and efficiency. Guidance consistency matters here—any pullback on FY28 targets or slower cartridge ramp would signal the market overestimated near-term upside. Conversely, a confident reaffirmation (or upgrade) would support the Street's 27% upside view.
What the Street says
Since last quarter: the filing scan
1 · Formycon biosimilar partnership (Jul 14)
OneSource announced a strategic manufacturing partnership with Formycon AG for biosimilar production. New contract wins are part of the growth narrative; this is operationally routine but adds to the CDMO revenue pipeline for FY27–28.
2 · DRL semaglutide supply clarity (Jul 9)
Dr. Reddy's flagged a delay in commercial semaglutide supplies to OneSource. The company immediately clarified: no material financial or operational impact. This signal matters—OneSource's own India/Canada launches are on track and supply-independent. Semaglutide risk is priced in; no fresh concern.
3 · Routine FDA inspection (Jul 2) & auditor reappointment (Sep 24)
Sterile product facility in Bengaluru underwent scheduled cGMP inspection; no compliance issues reported. BSR & Co LLP appointed as statutory auditors. Both routine; no red flags.
4 · Trading window closure (Sep 25) ahead of earnings
Standard SEBI compliance. No insider buying or selling noted in recent bulk/block deals. Promoter holding stable at 30.5% (unchanged QoQ). FII holdings up 169 bps to 19.19%; DII up 277 bps. Net foreign inflow into equities likely.
The close: setup and what to watch on Oct 27
OneSource lands Q2 earnings on a wall of analyst support (75% Buy, 27% upside) but into oversold price action (RSI 29.5, -38% from ATH). The stock's sell-off into result season is unusual for a growth story delivering 37%+ revenue growth; it signals either algorithmic liquidation in the pharma sector or genuine near-term valuation doubt. Q2 will clarify.
The three things the Street is watching: (1) Revenue persistence—does semaglutide stay on a 35%+ growth track, or does competitive margin pressure emerge? (2) Margin hold—new cartridge capacity ramp must not crack EBITDA %, else the FY28 40% target looks unachievable. (3) Guidance tone—management either steps up confidence (upgrade FY28 or add FY27 clarity) or holds steady. Any guidance pullback would confirm bears and validate the sell-off; reaffirmation would set up the Street consensus for a 27% re-rate as sentiment normalizes off oversold levels.
Watch also for: Q2 semaglutide contribution as a line item (the commercialization story needs to be quantified), second cartridge line efficiency commentary (early days, but any color on path to steady-state), and CDMO contract wins (Formycon and others). These will shape the FY28 outlook.